Fundamental Analysis Stories

BRQS
  over three weeks ago at Macroaxis 
By Raphi Shpitalnik
Borqs Technologies Return on Average Equity is relatively stable at the moment as compared to the past year. Borqs Technologies reported last year Return on Average Equity of 0.67. As of 12/28/2021, Return on Invested Capital is likely to grow to 0.78, while Earnings before Tax are likely to drop (37.9 M). Borqs Technologies is scheduled to announce its earnings tomorrow. Technology space may be getting hot again, let's check if Borqs Technologies is sending any bullish signals to investors. We will analyze why it could be a much better year for Borqs Technologies shareholders. Borqs Technologies current probability of bankruptcy is under 19 percent. Will retail investors continue to be optimistic, or should we expect a sell-off?
FCEL
  over three weeks ago at Macroaxis 
By Vlad Skutelnik
Fuelcell Energy Market Capitalization is relatively stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 464.89 Million. PPandE Turnover is expected to hike to 2.15 this year, although the value of Average Assets will most likely fall to nearly 433.7 M. Even with relatively steady technical and fundamental indicators, Fuelcell Energy is not utilizing all of its potentials. The current stock price chaos, may contribute to a medium-term swings for the stakeholders. Fuelcell Energy actively responds to the market. We can now summarize Fuelcell as a potential investment option for your portfolios.
AVCT
  over three weeks ago at Macroaxis 
By Vlad Skutelnik
In spite of comparatively weak fundamental indicators, American Virtual may actually be approaching a critical reversion point that can send shares even higher in January 2022. American Virtual Cloud odds of financial turmoil is under 47 percent. Will American Virtual private investors continue to trade in January?
CALM
  over three weeks ago at Macroaxis 
By Gabriel Shpitalnik
Even with relatively steady essential indicators, Cal-Maine Foods is not utilizing all of its potentials. The recent stock price chaos, may contribute to a medium-term swings for the stakeholders. The entity slowly supersedes the market. We can now summarize Cal-Maine as a potential investment option for your portfolios.
XXII
  over a month ago at Macroaxis 
By Gabriel Shpitalnik
If you have been following 22nd Century you may be considering locking in. Let's check if stable forward indicators will continue to push the price to rise for 22nd Century's stockholders. 22nd Century Group probability of distress is under 1 percent. Will 22nd Century stockholders continue to buy in January?
ACHR
  over a month ago at Macroaxis 
By Gabriel Shpitalnik
The next fiscal quarter end is expected on the 31st of December 2021. The stock is currently experiencing an active upward rally. While some of us are excited about industrials space, let's try to sum up Archer Aviation in greater detail to make a better evaluation of its fundamental indicators. We will evaluate why we are still confident in anticipation of a recovery. Will retail investors continue to hold, or should we expect a sell-off?
SMMT
  over a month ago at Macroaxis 
By Raphi Shpitalnik
The stock is currently undergoing an active upward rally. While some of us are excited about healthcare space, let's try to review Summit Therapeu ADR in greater detail to make a better evaluation of its fundamental indicators. We will analyze why it could be a much better year for Summit Therapeu shareholders. Will private investors continue to hold, or should we expect a sell-off?
BSGM
  over a month ago at Macroaxis 
By Ellen Johnson
Biosig Technologies Working Capital is relatively stable at the moment as compared to the past year. The company's current value of Working Capital is estimated at 26.14 Million. Book Value per Share is expected to hike to 0.94 this year, although the value of Earnings before Tax will most likely fall to (53.6 M). If you have been following Biosig you may be considering acquiring. Let's check if steady technical and fundamental indicators will continue to push the price to hike for Biosig Technologies' stakeholders. The company current odds of distress is under 47 percent. Will stakeholders continue to be optimistic, or should we expect a sell-off?
ELYM
  over a month ago at Macroaxis 
By Vlad Skutelnik
The next fiscal quarter end is expected on the 31st of December 2021. The stock continues to experience an active upward rally. While some of us are excited about healthcare space, let's try to summarize Eliem Therapeutics in greater detail to make a better evaluation of its fundamental indicators. We will evaluate why recent Eliem Therapeutics price moves suggest a bounce in January. Eliem Therapeutics slowly supersedes the market. We can now summarize Eliem as a potential investment option for your portfolios.
BTBT
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Bit Digital Total Assets are comparatively stable at the moment as compared to the past year. Bit Digital reported Total Assets of 39.89 Million in 2020. Assets Non Current is likely to gain to about 33.6 M in 2021, whereas Average Equity is likely to drop slightly above 17.3 M in 2021. Bit Digital is scheduled to announce its earnings tomorrow. The next earnings report is expected on the 29th of March 2022. While some of us are getting worried about technology space, it is reasonable to review Bit Digital using its current fundamental data. We will evaluate if Bit Digital shares are reasonably priced going into January. This firm current odds of distress is over 62%. Are Bit Digital private investors still optimistic?